
| Disease Domain | Count |
|---|---|
| Nervous System Diseases | 5 |
| Neoplasms | 4 |
| Immune System Diseases | 1 |
| Infectious Diseases | 1 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 6 |
| Chemical drugs | 1 |
| Monoclonal antibody | 1 |
Target |
Mechanism CAIX inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date01 Jan 1966 |
Mechanism 5-HT1B receptor agonists [+2] |
Active Org. |
Originator Org. |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism RXRs agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date05 May 2025 |
Sponsor / Collaborator |
Start Date15 Dec 2024 |
Sponsor / Collaborator |
Start Date01 Nov 2024 |
Sponsor / Collaborator |


| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Ibuprofen ( CAIX x COX-1 x COX-2 ) | Head and Neck Neoplasms More | Preclinical |
SET2 ( TRPV2 ) | Heart Diseases More | Preclinical |
Tributyltin salicylate ( RXRs ) | Neoplasms More | Preclinical |
Agmatine ( 5-HT1B receptor x 5-HT2A receptor x nNOS ) | Depressive Disorder More | Preclinical |
NG-Nitro-L-Arginine Methyl Ester ( NOSs ) | Hypertension More | Preclinical |





